Targeted Oncology3h
Pembrolizumab/Chemo Continues to Impress in NSCLC With 5-Year Updates
During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses phase 3 trials of combinations in the non–small cell lung ...
MedPage Today5h
Diet and Prostate Cancer; TTFields OK'd for NSCLC; Cancer Studies Retracted
The FDA approved a wearable tumor-treating fields (TTFields) device (Optune Lua) for concurrent use with a PD-1/PD-L1 ...
JD Supra5h
Novacure’s Wearable Lung Cancer Treatment Device, Optune Lua, Receives FDA Approval
The FDA has granted approval for Novocure‘s wearable medical device, Optune Lua, designed to treat advanced non-small cell ...
The American Journal of Managed Care12h
Biomarker Discovery and Exploration for SCLC
Panelists discuss how biomarker testing is currently utilized in the management of patients with small cell lung cancer (SCLC), including its timing within the treatment journey, while also exploring ...
Understanding how deadly lung cancers control the local immune system
Northwestern Medicine scientists have discovered how a protein in a deadly type of lung cancer can control how the immune ...
MassDevice1d
Novocure wins FDA nod for lung cancer treatment wearable
Novocure announced on Tuesday that the FDA treated its Optune Lua wearable device for treating metastatic non-small cell lung ...
NovoCure scoops FDA approval on wearable for metastatic cancer treatment
Optune Lua received FDA approval based on data from the pivotal LUNAR trial which demonstrated significant median OS ...
The Meadville Tribune1d
Lung cancer screenings save lives, but most people don’t know about them
A significant weapon in the fight against lung cancer may be going to waste, as a survey revealed most Americans aren’t aware ...
Targeted Oncology2d
FDA Oks Optune Lua for Use With PD-1/PD-L1 Inhibitors in Metastatic NSCLC
Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors ...
FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients
NovoCure's Optune Lua, a tumor-treating fields device, gains FDA approval for use with PD-1/PD-L1 inhibitors or docetaxel in ...
eLife3d
Phosphodiesterase 1A physically interacts with YTHDF2 and reinforces the progression of non-small cell lung cancer
The work presented will be of interest to cancer biologists and more broadly to those interested in NSCLC translational studies. Non-small cell lung cancer (NSCLC) is the most common subtype of lung ...
News Medical6d
Harnessing neural networks to forecast treatment outcomes in small cell lung cancer
As immunotherapy makes breakthrough progress in the treatment of small cell lung cancer (SCLC), predicting treatment outcomes has become a focal point in clinical practice. Immunotherapy combined with ...